Efficacy of mosapride citrate with polyethylene glycol solution for colonoscopy preparation
Efficacy of mosapride citrate with polyethylene glycol solution for colonoscopy preparation
复制标题
DOI：
10.3748/wjg.v18.i20.2517
复制
发表时间：
2012-05-28
影响因子：
4.3
通讯作者：
Yamao, Kenji
中科院分区：
文献类型：
--
作者：
Tajika, Masahiro;Niwa, Yasumasa;Yamao, Kenji
目的：评价柠檬酸莫沙必利用于结肠镜检查前肠道准备的有效性和安全性。方法：我们进行了一项随机、双盲、安慰剂对照研究。在接受结肠镜检查的2 5 0例患者中，12 4例随机接受2 L聚乙二醇加15 mg莫沙必利(莫沙必利组)，12 6例接受L聚乙二醇2 0 0 mg加安慰剂(安慰剂组)。患者完成了一份问卷，报告了肠道准备过程的可接受性和耐受性。根据Aronchick的标准，结肠镜检查人员使用5分标准来评估肠道准备的效果。主要终点是最佳的肠道准备比率(优/良/可vs.差/差)。结果：共有249名患者进入分析。在莫沙必利组中，左半结肠的最佳肠道准备率显著高于安慰剂组(78.2%比65.6%，P<；0.05)，但右半结肠的最佳肠道准备率(76.5%比66.4%，P=0.08)。排除重度便秘患者后，左右结肠的肠道准备情况有显著差异(82.4%vs66.7%，80.8%vs67.5%，P<；0.05，P<；0.01)。两组不良事件的发生率相似。在有结肠镜检查经验的亚组中，莫沙必利组的患者中感到当前制剂比安慰剂组更容易的患者明显更多(34/72名患者比24/74名患者，P<；0.05)。结论：柠檬酸莫沙必利可能是一种有效且安全的辅助剂，可以改善肠道准备的质量，特别是在没有严重便秘的患者。(C)2012年白石登。版权所有。
AIM: To evaluate the efficacy and safety of adjunctive mosapride citrate for bowel preparation before colonoscopy.METHODS: We conducted a randomized, double-blind, placebo-controlled study with mosapride in addition to polyethylene glycol (PEG)-electrolyte solution. Of 250 patients undergoing colonoscopy, 124 were randomized to receive 2 L PEG plus 15 mg of mosapride citrate (mosapride group), and 126 received 2 L PEG plus placebo (placebo group). Patients completed a questionnaire reporting the acceptability and tolerability of the bowel preparation process. The efficacy of bowel preparation was assessed by colonoscopists using a 5-point scale based on Aronchick's criteria. The primary end point was optimal bowel preparation rates (scores of excellent/good/fair vs poor/inadequate).RESULTS: A total of 249 patients were included in the analysis. In the mosapride group, optimal bowel preparation rates were significantly higher in the left colon compared with the placebo group (78.2% vs 65.6%, P < 0.05), but not in the right colon (76.5% vs 66.4%, P = 0.08). After excluding patients with severe constipation, there was a significant difference in bowel preparation in both the left and right colon (82.4% vs 66.7%, 80.8% vs 67.5%, P < 0.05, P < 0.01). The incidence of adverse events was similar in both groups. Among the subgroup who had previous colonoscopy experience, a significantly higher number of patients in the mosapride group felt that the current preparation was easier compared with patients in the placebo group (34/72 patients vs 24/74 patients, P < 0.05).CONCLUSION: Mosapride citrate may be an effective and safe adjunct to PEG-electrolyte solution that leads to improved quality of bowel preparation, especially in patients without severe constipation. (C) 2012 Baishideng. All rights reserved.